Overview

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

Single centre, double-blind, randomised, placebo-controlled study of two dosage regimens of BIA 2-093 - 1800 mg (Group 1) and 2400 mg (Group 2) - in two groups of healthy male volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Bial - Portela C S.A.

Treatments:

Eslicarbazepine acetate